Atara Biotherapeutics, Inc. current report, 14 June 2018

Full document

Atara Biotherapeutics, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Form 8-K reports on the Annual Meeting of Stockholders held by Atara Biotherapeutics, Inc. on June 14, 2018. The filing details the outcomes of votes submitted to security holders regarding corporate governance and financial oversight.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the results of the stockholder vote and does not contain financial performance data.

Material Changes and Voting Results

The following matters were voted upon at the Annual Meeting:

  • Election of Directors: Stockholders elected three nominees to serve until the 2021 annual meeting.
    • Eric L. Dobmeier: 34,196,186 votes For; 2,206,082 votes Withheld; 2,540,596 Broker Non-Votes.
    • William K. Heiden: 34,534,362 votes For; 1,867,906 votes Withheld; 2,540,596 Broker Non-Votes.
    • Beth Seidenberg, M.D.: 34,435,253 votes For; 1,967,015 votes Withheld; 2,540,596 Broker Non-Votes.
  • Ratification of Independent Auditor: Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
    • Results: 38,933,305 votes For; 7,722 votes Against; 1,837 Abstentions.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. For a more complete description of the matters voted upon, the filing references the definitive proxy statement filed on April 26, 2018.

Key Facts for Investor Verification

  • Confirm the tenure of the newly elected directors (Eric L. Dobmeier, William K. Heiden, and Beth Seidenberg, M.D.) extends through the 2021 annual meeting.
  • Verify that Deloitte & Touche LLP is the appointed auditor for the fiscal year ending December 31, 2018.
  • Review the definitive proxy statement filed on April 26, 2018, for detailed background on the nominees and the audit firm.